Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures
Pomerantz LLP has launched an investigation into EyePoint, Inc. (NASDAQ: EYPT) regarding potential securities fraud or unlawful business practices. The probe follows two significant clinical setbacks for the company's drug candidate, DURAVYU™. In August 2026, the LUGANO Phase 3 trial failed to meet visual acuity benchmarks compared to Regeneron Pharmaceuticals' Eylea, causing a nearly 67% drop in share price. A second blow occurred in October 2026 when the LUCIA Phase 3 trial also failed to demonstrate non-inferiority against the standard of care. In response to these failures, EyePoint terminated its late-stage wet AMD clinical program and announced a massive 53% workforce reduction to pivot toward diabetic macular edema programs. The stock plummeted over 85% following the second announcement.